1. Introduction {#sec1-nutrients-11-01072}
===============

Skeletal muscle is a dynamic tissue that adapts to external conditions and reacts to acute and long-term physical activity and feeding conditions \[[@B1-nutrients-11-01072]\]. Maintenance of muscle mass is not only important for athletes, but also for health and aging \[[@B2-nutrients-11-01072]\]. In particular, resistance training using a repeated high-weight stimulus optimizes the preservation of muscle mass that is correlated with body strength \[[@B3-nutrients-11-01072]\]. The underlying mechanism of adaptation is an increase in muscle protein synthesis (MPS) stimulated through mechanical load, which can be further augmented by additive protein supplementation \[[@B4-nutrients-11-01072]\]. Amino acids are required for protein synthesis. Leucine, a branched-chain amino acid (BCAA), has been shown to be a prerequisite stimulator of the mammalian target of rapamycin (mTOR) signaling pathway, which plays a critical role in MPS \[[@B5-nutrients-11-01072],[@B6-nutrients-11-01072]\].

Besides the contractile muscle components, passive tissues like bone, cartilage, ligaments, and tendons also adapt to resistance training \[[@B7-nutrients-11-01072]\]. In this context, Mackey et al. \[[@B8-nutrients-11-01072]\] showed that the synthesis of collagen in fibroblasts behaves similarly to MPS after a single bout of resistance training. Collagen is the most represented protein in the human body (30% of the protein concentration). It is an important element of the extracellular matrix (ECM) of skeletal muscle and tendons and is mainly responsible for their functionality in terms of force transmission, flexibility, and adaptation \[[@B9-nutrients-11-01072]\]. Thus, to ensure muscle fiber strength transmission, the ECM structures need to adapt in response to resistance training.

The benefit of collagen supplementation on collagen synthesis regarding tendon architecture has been demonstrated by various studies through the analysis of injured participants \[[@B10-nutrients-11-01072],[@B11-nutrients-11-01072]\]. Studies have reported less joint pain perception after collagen peptide supplementation in healthy active participants and in patients with osteoarthritis \[[@B12-nutrients-11-01072],[@B13-nutrients-11-01072],[@B14-nutrients-11-01072],[@B15-nutrients-11-01072],[@B16-nutrients-11-01072],[@B17-nutrients-11-01072]\], which could be of interest for those involved in elite sport. Clifford et al. \[[@B18-nutrients-11-01072]\] reported a faster recovery from jumping exercise and a tendency to reduce muscle soreness after collagen supplementation.

The beneficial effects of collagen supplementation on passive structures are associated with higher muscle strength following an improvement in force transmission. A study by Zdzieblik et al. \[[@B19-nutrients-11-01072]\] was, to the best of our knowledge, the first study to find a positive effect of collagen supplementation on strength and body composition. In a double-blind controlled trial, 53 elderly men (age: 72.2 ± 4.7 years) completed a 12-week resistance training intervention in combination with supplementation with 15 g of collagen or a placebo, resulting in significantly higher gains in fat-free mass (FFM) and muscle strength in the collagen peptide group. However, the underlying mechanism by which collagen peptides act on muscle protein metabolism remains unclear. Collagen is rich in non-essential amino acids, like proline and glycine, and relatively poor in essential amino acids like leucine, the main trigger for MPS.

Proteomic analysis methods have been increasingly developed and used to provide insight into molecular pathways and analyze responses to physical activity or nutrients \[[@B20-nutrients-11-01072],[@B21-nutrients-11-01072],[@B22-nutrients-11-01072],[@B23-nutrients-11-01072]\]. The advantage of proteomic analysis based on mass spectrometry is the large number of proteins identified, which provides information about all processes with no need to select specific pathways.

To obtain novel information about long-term adaptations and changes in protein content in response to collagen hydrolysate supplementation in combination with hypertrophy resistance training, we designed a double-blind, randomized, placebo-controlled trial and analyzed muscle proteome before and after a 12-week intervention.

2. Materials and Methods {#sec2-nutrients-11-01072}
========================

2.1. Experimental Design {#sec2dot1-nutrients-11-01072}
------------------------

The purpose of this double-blind, randomized, placebo-controlled trial was to investigate the effects of 12 weeks of hypertrophy resistance training combined with collagen supplementation on the proteome of the skeletal muscle. As this was part of a larger investigation project, other parameters, like immune histochemical or transcriptome analysis, were analyzed but will be the content of future publications \[[@B24-nutrients-11-01072]\]. In this trial, participants completed a 12-week progressive hypertrophy training intervention period with three controlled training sessions per week. All supervised training sessions included the following exercises in different orders: squat (SQ), dead lift (DL), bench press (BP), rowing (R) with barbells, and knee extensions. After a standardized warm-up, one set of 10 repetitions at 50% of the participant's 1-repetition maximum (RM) was performed followed by three sets of 10 repetitions at 70% 1-RM with a 2 min break between sets.

Before and after each intervention period, which contained at least 32 training sessions over 12 weeks, three standardized test days were completed. The test protocols included anthropometric measurements, isokinetic strength testing, 1-RM-testing, and muscle biopsies. A timeline of the test days including muscle biopsies is shown in [Figure 1](#nutrients-11-01072-f001){ref-type="fig"}.

During the intervention period, a three-day self-reported nutrition diary was used to evaluate the nutritional intake of the participants. The documentation included three consecutive days, including one day on the weekend and two days during the week. The diaries were evaluated to assess daily calories, carbohydrate, fat, and protein intake with PRODI^®^ 6.0 (Nutri-Science GmbH, Freiburg, Germany).

2.2. Participants {#sec2dot2-nutrients-11-01072}
-----------------

Twenty-five healthy sports students participated in the study. To be included in the study, participants had to have basic knowledge of the technical skills required for barbell use, and they had to reach a squat performance of at least 100% of their own body weight. Participants were randomly assigned either to the collagen peptide (COL) (*n* = 12) or placebo (PLA) (*n* = 13) group.

The sample size of *n* = 25 (COL: *n* = 12, age: 24.4 ± 2.3 years, body height: 185.8 ± 5.0 cm, body mass: 81.4 ± 6.6 kg; PLA: *n* = 13, age: 23.9 ± 2.9 years, body height: 184.3 ± 5.0 cm, body mass: 77.9 ± 4.1 kg) was used for the experimental trial proteome analysis. Subjects were informed about the study design and possible risks and provided their written informed consent. None of them had any health restrictions that were expected to influence the results. The Ethical Advisory Committee of the sport science faculty of the Ruhr-Universität Bochum approved the study protocol.

2.3. Supplementation {#sec2dot3-nutrients-11-01072}
--------------------

The supplement administered to the intervention group (*n* = 12) contained 15 g collagen hydrolysate provided by GELITA AG (Bodybalance™, Eberbach, Germany), whereas the subjects in PLA (*n* = 13) received a non-caloric silicon dioxide supplement. The participants consumed the collagen supplement or placebo daily during the 12-week intervention period. On training days, the supplement was consumed dissolved in 250 mL water under observation immediately after each training session. Participants were instructed not to consume additional caloric foods and beverages within 60 min after finishing training to avoid any cross interactions. On days without training, the supplement was taken at a similar time point to distribute the intake and allow about 24 h between ingestions.

2.4. Test Protocols {#sec2dot4-nutrients-11-01072}
-------------------

Three different test days were absolved in the same order and on the same weekday before and after the intervention period ([Figure 1](#nutrients-11-01072-f001){ref-type="fig"}). Following a 12-h fasting period, total body mass (BM), fat-free body mass (FFM), and fat mass (FM) were determined using a bioelectrical impedance analysis system (InBody 770, JP Global Markets GmbH, Eschborn, Germany). After a small self-prepared breakfast, 1-RM testing was performed using the method described by Kreamer et al. \[[@B25-nutrients-11-01072]\] for SQ, DL, BP, and R.

After a familiarization session, leg extension maximal voluntary isometric contraction (MViC) testing was performed using only the right leg with a 60° knee flexion angle on a dynamometer (Isomed 2000, D and R GmbH, Hemau, Germany).

Before the participants completed the last test day, three training sessions were performed at 50% 1-RM to learn the training procedures. The first training session at 70% 1-RM was completed on the third test day combined with muscle biopsies.

After a 12-h fasting period, participants provided a venous blood sample and then consumed a standardized breakfast provided by the investigators. To detect non-responders, a venous blood sample was again taken 2 h after supplement ingestion to determine the concentration of hydroxyproline, an amino acid that frequently appears in collagen hydrolysate \[[@B10-nutrients-11-01072],[@B26-nutrients-11-01072]\]. Next, a muscle biopsy was taken standardized percutaneously from the vastus lateralis muscle of the right leg under local anesthesia (Xylocitin^®^ 2% with Epinephrine, mibe GmbH, Brehna, Germany) with a 5 mm Bergstrøm needle, as described previously \[[@B27-nutrients-11-01072]\]. Muscle samples were cut into a coherent piece of approximately 30 mg and immediately frozen as native tissue in cooled liquid nitrogen and stored at −80 °C until proteome analysis. Immediately after the muscle biopsies, the participants performed a training session at 70% 1-RM followed by ingestion of the collagen or placebo supplement. Two hours later, another blood sample was collected and a muscle biopsy was performed. The second muscle biopsy was taken 3 cm proximal to the previous cut from the same leg. The proteome analysis was performed with the muscle sample collected before training in the fasted state to analyze longitudinal differences.

2.5. Proteomics {#sec2dot5-nutrients-11-01072}
---------------

Muscle samples (25--50 mg) were pulverized in liquid nitrogen and homogenized on ice and resuspended in urea buffer (7 M urea, 2 M thiourea, 20 mM Trisbase pH 8.5) to produce an accurate lysis. Resuspended samples were sonicated 6 times for 10 s each, with 10 s rest on ice to support the lysis process. The protein concentration was determined using the Bradford assay.

In solution, digestion with trypsin was conducted as described in Winter et al. \[[@B28-nutrients-11-01072]\]. Briefly, samples were reduced with dithiothreitol (DTT) for 20 min at 56 °C and alkylated at room temperature (RT) using iodoacetamide (IAA). Trypsin was added in a sample/enzyme ratio of 1:40. Digestion occurred overnight at 37 °C and was stopped by acidification. The peptide concentration was determined by amino acid analysis.

We used 200 ng of peptides from each sample for label-free quantitative liquid chromatography-mass spectrometry (LC-MS) analysis. Liquid chromatography was performed on an UltiMate 3000 RSLC nano LC system (Dionex, Idstein, Germany), as described in Winter et al. \[[@B28-nutrients-11-01072]\]. The high-performance liquid chromatography (HPLC) system was online-coupled to the nano electrospray ionization (ESI) source of a Q Exactive mass spectrometer (Thermo Fisher Scientific, Schwerte, Germany). In the ESI-tandem mass spectrometry (MS/MS) analysis, full MS spectra and MS/MS scans were recorded, as described in Chen et al. \[[@B29-nutrients-11-01072]\].

Progenesis Software (Progenesis QI for Proteomics, Nonlinear Dynamics Ltd., Newcastle upon Tyne, UK) was used for the quantification of peptides. The data were analyzed as described in Winter et al. \[[@B28-nutrients-11-01072]\]. Spectra were identified by the Mascot search engine (version 2.5, Matrixscience, London, UK) using the SwissProt part of the UniProtKB \[[@B30-nutrients-11-01072]\] for homo sapiens (release 2017_6, containing 20,206 entries and decoys). Decoys were generated by the DecoyDatabaseBuilder for each protein \[[@B31-nutrients-11-01072]\]. The mass tolerance was set to 5 ppm for precursor ions and 20 mmu for fragment ions. Due to the sample preparation steps, carbamidomethylation of cysteine was set as a fixed modification, and oxidation of methionine was set as a variable modification. Two tryptic miscleavages were considered in the analysis. The peptide identifications were imported into Progenesis (Nonlinear Dynamics Ltd., Newcastle upon Tyne, U.K.) and assigned to the respective features. Progenesis uses the principle of protein grouping, when one peptide cannot unambiguously be assigned to one single protein, but is unique for a group of proteins. In the case of protein grouping, only the first accession was used for protein assignment and for the evaluation of the results. Nevertheless, all assigned accessions are reported in the respective tables and materials.

False discovery rate (FDR) was estimated separately for each search using the Protein Inference Algorithm (PIA) \[[@B32-nutrients-11-01072],[@B33-nutrients-11-01072],[@B34-nutrients-11-01072]\]. Here, the Mascot Ion Score thresholds for 1% FDR were determined and taken as cut off values for peptide identification. Proteins quantified with an ANOVA *p* value ≤ 0.05 were considered to be significantly differently expressed and were used for further evaluation.

2.6. Statistical Analysis {#sec2dot6-nutrients-11-01072}
-------------------------

Data are presented as means and standard deviations. Statistical analyses were performed using the statistical program SPSS Statistics 25 (IBM, Armonk, New York, USA). The Kolmogorov--Smirnoff test was used to test the normal distribution of variables (differences). A two-way ANOVA with repeated measurements (time × treatment) was used to analyze significant differences between groups over time. If the ANOVA showed a significant effect (*p* ≤ 0.05), post-hoc tests were performed using paired *t*-tests (pre vs. post), and *t*-tests were used for independent samples to detect differences between groups. The level of statistical significance was set at *p* ≤ 0.05 and this was alpha-adjusted (Bonferroni correction).

Cut-off values for proteins that were significantly regulated between the two groups were determined by a fold change (FC) of at least 1.5 and a *q* value ≤ 0.05 (corrected ANOVA *p* value in accordance with Benjamini Hochberg) \[[@B35-nutrients-11-01072],[@B36-nutrients-11-01072]\]. For further analysis, PANTHER (<http://www.pantherdb.org/>) (University of Southern California, Los Angeles, CA, USA) free analysis tools were used for Gene Ontology categorization and pathway analysis \[[@B37-nutrients-11-01072]\].

3. Results and Discussion {#sec3-nutrients-11-01072}
=========================

The analysis of the blood samples revealed significant increases in hydroxyproline for each participant in COL two hours after ingesting the collagen peptide (pre: 33.3 ± 19.7 µmol/L, post: 95.8 ± 27.1 µmol/L; *p* ≤ 0.0125) compared to participants in the PLA group (pre: 14.4 ± 6.4 µmol/L, post: 14.3 ± 11.3 µmol/L; *p* = 0.956), indicating that all subjects were able to absorb the hydrolyzed collagen \[[@B10-nutrients-11-01072]\].

The dietary assessment showed no differences in caloric intake or macronutrients between the groups. The average protein intake over three days including the supplement was 135.1 ± 29.0 g/day in COL and 145.8 ± 52.7 g/day in PLA (*p* = 0.557), representing an adequate and equal protein intake of 1.66 g/kg/day (COL) and 1.86 g/kg/day (PLA).

At the beginning of the 12-week intervention period, no statistical differences existed between COL and PLA for any anthropometric or strength parameter ([Table 1](#nutrients-11-01072-t001){ref-type="table"}). From pre to post (main effect *p* ≤ 0.05) the whole cohort increased significantly in all parameters. ANOVA with repeated measurements showed significant interaction effects (*p* ≤ 0.05) for BM, FFM, and R, and trends for an interaction effect for SQ (*p* = 0.073), BP (*p* = 0.099), and MViC (*p* = 0.066), which increased slightly more in COL than in PLA, respectively. FM and DL showed no interaction effect between groups. Post-hoc *t*-tests with the Bonferroni correction (to *p* ≤ 0.0125) revealed no significant differences between groups in BM, FFM, and R after 12 weeks. FFM only increased in COL, whereas no difference was found in PLA.

Considering the differences between groups, delta values from pre to post are given in [Table 2](#nutrients-11-01072-t002){ref-type="table"}. Individuals in COL gained significantly more BM and FFM in contrast with those in PLA. Individuals in COL had a significantly higher strength increase in R compared to those in PLA ([Table 2](#nutrients-11-01072-t002){ref-type="table"}).

The study by Zdzieblik et al. \[[@B19-nutrients-11-01072]\] showed a clear improvement in isokinetic quadriceps strength, a greater loss in FM and higher gains in FFM in 26 sarcopenic older men supplementing 15 g collagen peptides per day during a 12-week training intervention compared with a placebo group (*n* = 27). In our study, FFM also increased to a higher extend in COL compared with PLA, while strength only slightly increased further in COL compared with PLA, suggesting that mechanisms are more pronounced in the elderly populations than in younger healthy men. Because collagen has a high impact on tendon tissues \[[@B10-nutrients-11-01072],[@B11-nutrients-11-01072]\], it is possible that exercises that stimulate reactive power of the tendons would have shown clearer effects of collagen peptide supplementation \[[@B18-nutrients-11-01072]\]. The strength tests used in this study only slightly depend on reactive forces and might therefore have underestimated possible effects of the supplement on tendon tissues. Another part of our study analyzed the muscle fiber cross-sectional area and showed no differences between groups \[[@B24-nutrients-11-01072]\], underpinning the hypothesis that adaptations induced by collagen supplements do not affect the muscle cell per se but structural components of muscle tissue surrounding the cells.

Overall comparisons of 1377 proteins or protein groups (proteins and protein groups are referred to as "proteins" in the following text for better readability) were quantified in our analysis using Progenesis QI for proteomics.

The baseline data of the two groups were compared against each other to identify any differences on the proteomic level due to the cohort composition itself, to prevent possible data misinterpretation due to cohort variability. In total, three proteins were significantly increased in PLA compared with COL prior the intervention due to biological variability ([Table 3](#nutrients-11-01072-t003){ref-type="table"}). In COL, no higher abundant proteins could be identified compared with PLA. In order to avoid possible influences of the different baseline values, these proteins were excluded from further data analysis.

The distribution of regulated proteins before and after 12 weeks of resistance training and supplementation differed; there were 17 downregulated proteins in COL compared to 18 downregulated proteins in PLA, of which 9 proteins appeared in both groups ([Figure 2](#nutrients-11-01072-f002){ref-type="fig"}a). We found that 293 proteins were highly regulated in COL after the 12-week intervention, of which 72 were also of higher abundance in PLA. These changes thus resulted from the hypertrophy training intervention. Hence, 221 proteins were only upregulated in COL compared to 44 proteins in PLA, showing a pronounced difference in the number of upregulated proteins between the two groups ([Figure 2](#nutrients-11-01072-f002){ref-type="fig"}). The direct comparison between COL and PLA after 12 weeks of supplementation and resistance exercise training revealed no significant different proteins.

For a deeper proteomic characterization of our data set Gene Ontology (GO) categorization was performed using PANTHER (default settings using Fisher's exact and FDR-correction) in respect to three different aspects: Cellular components, biological processes, and molecular functions \[[@B37-nutrients-11-01072]\]. To provide a better overall view of the large number of hits, the REVIGO tool \[[@B38-nutrients-11-01072]\] was used to sum classes ranked by FDR ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}a--c). The downregulated proteins ([Figure 2](#nutrients-11-01072-f002){ref-type="fig"}a) were not considered because the low number (PLA = 9; COL = 8) of hits was not appropriate for group allocations.

Higher abundant proteins in the intersection ([Figure 2](#nutrients-11-01072-f002){ref-type="fig"}b) were assigned to GO categories often found in response to resistance training. For example, upregulated proteins in the GO category "biological processes" ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}a) included the response to cytokines or protein modifications, which are in line with other study outcomes \[[@B39-nutrients-11-01072],[@B40-nutrients-11-01072]\]. No subclass of the aspects "molecular functions" and "cellular components" showed specific categories associated with skeletal muscle. Upregulated proteins in PLA showed no direct association with the skeletal muscle system, although the upregulated proteins in PLA in the biological processes category that could be classified into organonitrogen compound metabolic processes and nitrogen compound metabolic processes indicated some responses to an amino acid stimulus ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}c).

In contrast, annotation of upregulated proteins of COL included those associated with GO biological processes related to the skeletal muscle (muscle contraction and muscle system process) and protein modifications (protein ubiquitination, protein modification by small protein conjugation or removal) ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}b).

The annotated GOs for cellular components were similar in COL and PLA: extracellular parts, cytoplasm, intracellular, and vesicles. However, PLA contained a higher number of upregulated proteins associated with the terms mitochondria and mitochondrial matrix ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}c), and COL had a few upregulated proteins related to the GO category supramolecular fibers, which are superior to contractile fibers ([Figure 3](#nutrients-11-01072-f003){ref-type="fig"}b).

The GOs belonging to molecular function in COL also included categories directly related to the skeletal muscle fiber structure, like cytoskeletal protein binding and the structural constitution of muscle. Upregulated proteins in PLA were assigned with general categories, such as catalytic activity and coenzyme binding, with respect to their molecular function.

Overall, COL showed a strong association with annotations spanning contractile muscle fiber (sarcomere or cytoskeleton) in all three GO categories, whereas PLA showed none of them or not enough regulated proteins to form a category. To summarize, we observed considerable differences in the protein response due to collagen supplementation, as both groups performed the same training protocol.

A pathway analysis was performed using PANTHERs overrepresentation test with default settings and the "Reactome pathways" annotated data set. The main categories of significant regulated pathways (Cut off values: FDR ≤ 0.01, fold enrichment score ≥ 2.00 and at least three or more proteins assigned) are presented in [Figure 4](#nutrients-11-01072-f004){ref-type="fig"}. Most pathways were annotated to cell cycle, signal transduction, metabolism of proteins and immune system. Selected pathways that are relevant in the context of exercise training and adaptation according to the literature are listed in [Table 3](#nutrients-11-01072-t003){ref-type="table"} (complete list in [supplemental Table S1](#app1-nutrients-11-01072){ref-type="app"}). COL showed 192 pathways that are significantly overrepresented. In comparison, only one pathway was assigned to PLA according to the cut-off criteria, which was "metabolism" (fold enrichment = 3.70; FDR = 4.75 × 10^−3^).

Overrepresented pathways in COL showed many responses characteristic to exercise training and adaptation ([Table 4](#nutrients-11-01072-t004){ref-type="table"}). Of 192 significant pathways, 31 pathways were assigned to signal transduction. Several mitogen-activated protein kinases (MAPK) pathways were overrepresented that have been reported before in human skeletal muscle, after cycling or running exercise \[[@B41-nutrients-11-01072],[@B42-nutrients-11-01072]\]. MAPK cascades are activated through cellular stress such as muscle contraction and exercise. In particular, MAPK1 and MAPK3, also known as extracellular-signal regulated kinase (ERK) 2 and 1, are the key components of the MAPK/ERK cascade, which regulates cell growth and differentiation through influencing transcription, translation, and cytoskeleton structure \[[@B43-nutrients-11-01072]\]. Furthermore, signal transduction through protein kinase B (Akt) is upregulated in COL. The Akt/mTOR pathway is one of the most researched pathways on cell growth and is regarded as the main regulator of hypertrophy \[[@B44-nutrients-11-01072]\]. As expected after exercise, the immune system response increased cytokine signaling through interleukins to improve the regeneration process \[[@B45-nutrients-11-01072]\]. The metabolism of proteins belongs mainly to translational processes and protein folding, especially for cytoskeletal proteins. Overrepresented metabolic pathways are mainly glycolytic energy metabolism associated pathways as expected according to the chosen training stimulus \[[@B46-nutrients-11-01072]\].

Cellular response to external stimuli pathway, showed downstream cascades responding to stress, hypoxia and heat stress. Hypoxia inducible factor alpha 1 (HIF-1) is regulated through muscle oxygen concentration that decreased during exercise or injury. HIF-1 stimulates via erythropoietin (EPO) myoblast proliferation and muscle recovery after injury and is important for muscle repair and regeneration \[[@B47-nutrients-11-01072]\]. Furthermore, heat shock transcription factor 1 (HSF1) is present in multiple pathways. HSF1 acts as the major transcription factor in human muscle cells in response to stress. Striated and smooth muscle contraction pathways are also significantly overrepresented after 12 weeks of strength training and collagen supplementation.

To create an initial understanding of the related mechanisms, proteins belonging to the term contractile fibers (assigned according to PANTHER) were further analyzed, since proteins of this category were detected in both groups. Only two proteins from 44 differentially upregulated proteins of PLA were assigned to this type, in COL 26 out of 221 higher abundant proteins were annotated to the term contractile fibers ([Table 5](#nutrients-11-01072-t005){ref-type="table"} and [Table S2](#app1-nutrients-11-01072){ref-type="app"}). One of the upregulated proteins in PLA was alpha-crystallin B chain, which often increases to protect the cytoskeleton and myofibril structure after muscle damage caused by eccentric exercise \[[@B48-nutrients-11-01072]\]. The other protein belonging to this term detected in PLA was leiomodin-2, which promotes the polymerization of actin filaments in skeletal muscle cells \[[@B49-nutrients-11-01072]\].

In COL several proteins with different myofibrillar function were identified as being in higher abundance compared to PLA, e.g., myosin proteins (myosin regulatory light chain 2, myosin-8, myosin light chain 1/3) and actin-binding proteins (alpha-actinin-2, synaptopodin, tropomodulin-4), including tropomyosins (tropomyosin beta chain, tropomyosin alpha-3 chain). Many have already been observed before in proteome analyses after resistance exercise \[[@B50-nutrients-11-01072]\]. Troponin C and I were also found to be of higher abundance in COL. Troponin I is already known to be increased by chronic exercise and regulates the interaction between actin and myosin filaments \[[@B51-nutrients-11-01072]\]. One of the upregulated proteins belonging to the Z-disk (five proteins total) is myotilin, an important marker for remodeling the myofibril structures after exercise. Myotilin binds alpha-actinin-2 and PDZ and LIM domain protein 3 to control Z-disk organization \[[@B52-nutrients-11-01072]\]. Five sarcolemmal proteins showed an increased fold enrichment, including desmin, which has already been reported in other studies to be a responder to resistance exercise, which is relevant for force transmission through the cytoskeleton \[[@B28-nutrients-11-01072]\]. The cytoskeleton is not just a structural component but is also responsible for the communication between the muscle cells and the ECM \[[@B9-nutrients-11-01072]\]. Small muscular protein and smoothelin-like protein 1 were also upregulated in COL. These two proteins are associated with the costamere, being responsible for the force transmission, which is generated in the myofibrils and transferred to the ECM \[[@B53-nutrients-11-01072]\].

COL induced a higher abundance in proteins being associated with resistance training adaptations. These effects might be caused by the high hydroxyproline-peptide content of the collagen peptide supplementation, as Kitakaze et al. \[[@B54-nutrients-11-01072]\] were able to show an increase myoblast differentiation and myotube hypertrophy in murine skeletal muscle C2C12 cells by hydroxyproline-glycine-peptides.

The number of proteins belonging to relevant categories of the skeletal muscle (manually annotated) was significantly different between both groups, resulting in more relevant proteins for adaptation processes observed in COL compared with PLA.

Because participants in COL ingested 15 g collagen hydrolysate every day, collagen proteins and collagen-associated proteins that were differently expressed after 12 weeks are shown in [Table 6](#nutrients-11-01072-t006){ref-type="table"}. Collagen 6alpha2, fibronectin, and laminin subunit gamma 1 showed increased FC in both groups after 12 weeks as a result of resistance training. Laminins, collagens, as well as fibronectins are the main fibrous parts of the ECM. Fibronectin has many different functions, for example, organization of ECM structures, cell migration, and adhesion and tissue repair through fibroblast migration \[[@B55-nutrients-11-01072]\]. The increase in fibronectin after resistance training is consistent with other studies that reported increased values 72 h after exercise \[[@B56-nutrients-11-01072]\]. An increase in laminin was associated with myogenic differentiation in mice \[[@B57-nutrients-11-01072]\]. Consequently, both groups adapted their ECM protein production independently from collagen supplementation.

In contrast, collagen 5alpha1, collagen 15alpha1 and collagen 18alpha1 were only upregulated in COL, whereas PLA showed a fold enrichment of the protein lumican. Collagen 5alpha1 is a fibrillar collagen normally contained in collagen 1-rich regions, playing a critical role in fibrillogenesis and fibril organization \[[@B58-nutrients-11-01072]\]. It is mostly associated with Ehlers-Danlos syndrome, which is caused by a congenital mutation of the *col5a1* gene and is characterized by hyperextensibility of skin and joints \[[@B59-nutrients-11-01072]\]. Baghdadi et al. \[[@B60-nutrients-11-01072]\] identified collagen 5alpha1 in muscle stem cells as a regulator of the notch signaling pathway that is concerned with the prevention of satellite cell storage by repressing differentiation process initiated by myoD (myogenic differentiation 1) to maintain quiescence, in addition to the main function of organizing the structure of the ECM through collagen 1 formation. The FC of collagen 5alpha1, which is extremely high compared with all other proteins, should be considered with caution because data validation (using immunoblotting) is still missing, and proteomic analysis itself struggles with a high variability between individuals \[[@B61-nutrients-11-01072],[@B62-nutrients-11-01072]\].

The other protein belonging to the collagen family that was upregulated in COL is collagen 18alpha1. Together with collagen 15, it forms a collagen category named multiplexins, which is characterized by compounds with multiple triple-helix domains in containing non-collagenous parts. Collagen 18alpha1 is located next to collagen 4 in the basement membrane, occurs nearly ubiquitously in the human body, and seems to differ in function depending on the location \[[@B63-nutrients-11-01072]\]. It contains a non-collagen domain called endostatin, which is known to be a suppressor of angiogenesis and tumor growth \[[@B64-nutrients-11-01072]\]. Because of its inhibitory effect on tumor growth, endostatin has been well investigated in contrast to the function of collagen 18alpha1 in different tissues. Its role in skeletal muscle has not been directly investigated, but it is transferred from other tissues where it is the structural component of the basement membrane, binding ECM proteins like laminin.

Lumican, which was upregulated in PLA, is also a component of the ECM that binds to collagen 1 and affects collagen fibrillogenesis and therefore, the matrix assembly \[[@B65-nutrients-11-01072]\].

Connective tissue remodeling has been studied in previous years, as *collagen 1, 3*, and *4* genes are elevated after a single bout of exercise, but are unchanged after a second bout \[[@B66-nutrients-11-01072]\]. After 36 training sessions, we would have expected a higher abundance in these proteins caused by adaptation, but they were unaffected in both groups, and instead, other collagenous proteins were upregulated in both groups. This shows their importance not only for contractile fibers but also for passive structures, like the ECM around muscle cells, to adapt to the mechanical load \[[@B9-nutrients-11-01072]\]. The adaptation of the ECM seems to occur even without collagen supplementation, although more collagenous proteins were upregulated following COL supplementation.

4. Conclusions {#sec4-nutrients-11-01072}
==============

In conclusion, after 12 weeks of hypertrophy resistance exercise training in combination with collagen supplementation compared with a placebo, we found significantly higher BM and FFM and a slightly more pronounced increase in strength in COL compared with PLA. Individuals in COL showed a significantly higher number of upregulated proteins and significantly more pathways associated with resistance exercise compared with PLA after the intervention, indicating stronger effects for the combination of strength training and supplementation on the skeletal muscle proteome than strength training alone. In contrast to these considerable effects on the proteome, increments in muscle strength were not as clear. Further investigations are needed to clarify the role of collagen 5alpha1 in muscle adaptations to resistance training and collagen supplementation and its possible impact on strength. Furthermore, it would be interesting to compare different protein sources with regard to their metabolic effects and strength training adaptations.
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![Flow chart describing the experimental design. Pre- and post-testing consisted of three test days (TD1--3) separated by a 12-week intervention period with collagen or placebo supplementation each day and hypertrophy resistance training three days per week. MViC: Maximal voluntary isometric contraction; RM: Repetition Maximum.](nutrients-11-01072-g001){#nutrients-11-01072-f001}

![Venn diagrams showing different numbers of (**a**) significantly downregulated and (**b**) upregulated proteins in the placebo (blue) and collagen (green) groups after 12-week resistance exercise training and supplementation. The intersection represents proteins that were regulated in both groups.](nutrients-11-01072-g002){#nutrients-11-01072-f002}

![Gene Ontology (GO) analysis of proteins from the (**a**) intersection, (**b**) collagen group, and (**c**) placebo group after 12 weeks of resistance training and supplementation calculated by PANTHER. The false discovery rate (FDR) is marked with a dashed line at 0.10.](nutrients-11-01072-g003){#nutrients-11-01072-f003}

![Pie chart shows significantly overrepresented pathways in the collagen (COL) group after 12 weeks of resistance training and supplementation analyzed by PANTHER. Size of the different colored parts indicates number of assigned pathways.](nutrients-11-01072-g004){#nutrients-11-01072-f004}
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###### 

Results for body mass (BM), fat mass (FM), fat free mass (FFM), the squat test (SQ), dead lift (DL), bench press (BP), rowing (R), and isometric strength testing (MViC) before and after the 12-week intervention period. Data are presented for the collagen and placebo groups (means ± SD) as a pre- and post-test comparison. Statistical significance for interactions as determined by ANOVA was considered as *p* ≤ 0.05, and the level of significance for the post-hoc *t*-tests was set at *p* ≤ 0.0125 after Bonferroni correction.

  Characteristic   Collagen Group (*n* = 12)   Placebo Group (*n* = 13)   Interaction    Post-Test Difference between Groups                  
  ---------------- --------------------------- -------------------------- -------------- ------------------------------------- -------------- --------------
  BM (kg)          81.4 ± 6.6                  84.4 ± 6.3 \*              77.9 ± 4.1     79.4 ± 5.1 \*                         0.035          n.s. (0.039)
  FM (kg)          10.3 ± 3.6                  10.9 ± 4.1 \*              8.4 ± 2.2      9.4 ± 2.4 \*                          n.s. (0.534)   \-
  FFM (kg)         71.2 ± 5.7                  73.8 ± 5.3 \*              69.6 ± 4.0     70.3 ± 4.3 \*                         0.014          n.s. (0.080)
  SQ (kg)          114.3 ± 20.2                140.8 ± 24.3 \*            108.7 ± 8.3    126.3 ± 13.9 \*                       n.s. (0.073)   n.s. (0.084)
  DL (kg)          131.7 ± 19.6                156.3 ± 21.2 \*            128.0 ± 15.6   143.9 ± 10.6 \*                       n.s. (0.234)   \-
  BP (kg)          80.4 ± 14.0                 94.4 ± 15.6 \*             84.4 ± 13.9    94.2 ± 10.2 \*                        n.s. (0.099)   n.s. (0.987)
  R (kg)           85.0 ± 11.3                 98.3 ± 12.6 \*             91.2 ± 8.9     97.3 ± 8.1 \*                         0.025          n.s. (0.812)
  MViC (nM)        294.3 ± 56.3                323.6 ± 72.1 \*            260.7 ± 25.0   275.2 ± 31.3 \*                       n.s. (0.066)   n.s. (0.059)

\* significantly different to pre-test (post-hoc paired *t*-test with Bonferroni correction to *p* ≤ 0.0125). n.s. = not significant.
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###### 

Differences (mean ± SD) in post-test values between the collagen (COL) group and placebo (PLA) group in body mass (BM), fat mass (FM), fat free mass (FFM), the squat test (SQ), dead lift (DL), bench press (BP), rowing (R), and isometric strength testing (MViC) before and after the 12-week intervention period. Unpaired *t*-tests were used to detect differences between both groups after the intervention (level of significance was set to *p* ≤ 0.05).

  Exercise    Collagen Group   Placebo Group   Unpaired *t*-test
  ----------- ---------------- --------------- -------------------
  BM (kg)     3.01 ± 2.01      1.50 ± 1.29     0.035
  FM (kg)     0.58 ± 1.47      0.90 ± 1.09     n.s. (0.534)
  FFM (kg)    2.56 ± 2.22      0.70 ± 1.14     0.014
  SQ (kg)     26.5 ± 13.2      17.6 ± 9.9      n.s. (0.073)
  DL (kg)     24.5 ± 19.1      15.9 ± 13.9     n.s. (0.234)
  BP (kg)     14.0 ± 6.6       9.8 ± 5.5       n.s. (0.099)
  R (kg)      13.3 ± 8.7       6.1 ± 5.8       0.025
  MViC (nM)   29.4 ± 22.9      14.5 ± 14.3     n.s. (0.066)

n.s. = not significant.
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###### 

Upregulated proteins in the collagen (COL) and placebo (PLA) group showing baseline differences before the intervention.

  UniProt                                   Gene Name   Protein Description                  Fold Change (FC)          
  ----------------------------------------- ----------- ------------------------------------ ------------------ ------ ----
  Only upregulated in COL before 12 weeks                                                                              
                                            \-                                                                  \-     \-
  Only upregulated in PLA before 12 weeks                                                                              
  P10636                                    MAPT        Microtubule-associated protein tau   \-                 1.63   
  P02144                                    MB          Myoglobin                            \-                 1.71   
  P09493                                    TPM1        Tropomyosin alpha-1 chain            \-                 1.52   

nutrients-11-01072-t004_Table 4

###### 

Overrepresented pathways in the collagen (COL) group after 12 weeks of resistance training and supplementation. Main categories are shown with the number of annotated pathways and downstream pathways with the calculated fold enrichment and false discovery rate (FDR).

  Pathway                                                                                                               Number of Pathways   Fold Enrichment   FDR
  --------------------------------------------------------------------------------------------------------------------- -------------------- ----------------- ----------------
  **Cell Cycle**                                                                                                        **47**                                 
  **Signal Transduction**                                                                                               **31**                                 
   PIP3 activates AKT signaling                                                                                                              3.98              3.56 × 10^−3^
   MAPK family signaling cascades                                                                                                            5.22              7.42 × 10^−6^
   MAPK6/MAPK4 signaling                                                                                                                     9.65              1.47 × 10^−5^
   MAPK1/MAPK3 signaling                                                                                                                     6.09              1.63 × 10^−6^
   RAF/MAP kinase cascade                                                                                                                    6.22              1.37 × 10^−6^
   Regulation of RAS by GAPs                                                                                                                 12.63             2.48 × 10^−6^
  **Immune System**                                                                                                     **27**                                 
   MAP kinase activation                                                                                                                     7.57              7.58 × 10^−3^
   Cytokine signaling in immune system                                                                                                       3.71              7.00 × 10^−7^
   Signaling by Interleukins                                                                                                                 4.25              2.51 × 10^−6^
   Interleukin-1 family signaling                                                                                                            7.66              8.30 × 10^−6^
   Interleukin-1 signaling                                                                                                                   10.39             8.47 × 10^−7^
   MAP3K8 (TPL2)-dependent MAPK1/3 activation                                                                                                17.89             9.74 × 10^−3^
   Interleukin-12 family signaling                                                                                                           6.70              3.23 × 10^−2^
  **Metabolism of Proteins**                                                                                            **23**                                 
   Translation                                                                                                                               3.91              1.13 × 10^−3^
   Eukaryotic translation elongation                                                                                                         9.14              2.11 × 10^−5^
   Eukaryotic translation initiation                                                                                                         6.42              7.41 × 10^−4^
   Eukaryotic translation termination                                                                                                        6.16              6.39 × 10^−3^
   Protein folding                                                                                                                           7.63              2.41 × 10^−4^
   Post-chaperonin tubulin folding pathway                                                                                                   17.35             1.79 × 10^−3^
   Cooperation of prefoldin and TriC/CCT in actin and tubulin folding                                                                        17.89             3.86 × 10^−5^
   Formation of tubulin folding intermediates by CCT/TriC                                                                                    19.09             1.90 × 10^−4^
   Prefoldin mediated transfer of substrate to CCT/TriC                                                                                      21.21             1.74 × 10^−5^
   Post-translational protein modification                                                                                                   2.61              1.89 × 10^−6^
   UCH proteinases                                                                                                                           11.93             1.04 × 10^−7^
   Deubiquitination                                                                                                                          5.08              1.00 × 10^−5^
  **Metabolism**                                                                                                        **15**                                 
   The citric acid (TCA) cycle and respiratory electron transport                                                                            8.27              1.08 × 10^−7^
   Pyruvate metabolism and citric acid (TCA) cycle                                                                                           8.84              4.29 × 10^−3^
   Pyruvate metabolism                                                                                                                       12.72             4.76 × 10^−3^
   Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins                        7.76              2.13 × 10^−5^
   Respiratory electron transport                                                                                                            7.63              2.42 × 10^−4^
   Metabolism of amino acids and derivatives                                                                                                 6.8               4.19 × 10^−11^
   Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism                                                             10.37             2.29 × 10^−3^
   Glyoxylate metabolism and glycine degradation                                                                                             12.31             5.25 × 10^−3^
   Gluconeogenesis                                                                                                                           11.57             6.32 × 10^−3^
  **Cellular Response to external stimuli**                                                                             **11**                                 
   Cellular responses to stress                                                                                                              6.31              1.04 × 10^−10^
   Cellular response to hypoxia                                                                                                              12.72             7.28 × 10^−7^
   Oxygen-dependent proline hydroxylation of HIF-1α                                                                                          14.46             3.37 × 10^−7^
   Cellular response to heat stress                                                                                                          13.16             5.52 × 10^−8^
   HSF1 activation                                                                                                                           39.77             1.15 × 10^−5^
   HSF1-dependent transactivation                                                                                                            31.81             9.12 × 10^−8^
   Attenuation phase                                                                                                                         34.08             1.98 × 10^−5^
   Regulation of HSF1-mediated heat shock response                                                                                           7.12              9.56 × 10^−3^
   HSP90 chaperone cycle for steroid hormone receptors (SHR)                                                                                 13.63             6.36 × 10^−6^
  **Metabolism of mRNA**                                                                                                **11**                                 
  **Developmental Biology**                                                                                             **6**                                  
  **Gene Expression**                                                                                                   **6**                                  
  **Muscle Contraction**                                                                                                **3**                                  
   Striated muscle contraction                                                                                                               23.86             8.26 × 10^−8^
   Smooth muscle contraction                                                                                                                 10.91             7.55 × 10^−3^
  **Others**                                                                                                            **12**                                 
   CREB phosphorylation through the activation of CaMKII                                                                                     19.09             5.28 × 10^−3^
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###### 

Upregulated proteins belonging to the GO category "contractile fibers" in the collagen (COL) and placebo (PLA) groups.

  UniProt                                                    Gene Name   Protein Description                                             Fold Change   FDR
  ---------------------------------------------------------- ----------- --------------------------------------------------------------- ------------- -------
  Only upregulated in COL after 12 weeks of training                                                                                                   
  P35609                                                     ACTN2       Alpha-actinin-2                                                 1.57          0.006
  Q9GZV1                                                     ANKR2       Ankyrin repeat domain-containing protein 2                      1.62          0.025
  O95817                                                     BAG3        BAG family molecular chaperone regulator 3                      1.87          0.004
  O00499                                                     BIN1        Myc box-dependent-interacting protein 1                         1.79          0.000
  P17661; P07197                                             DESM        Desmin                                                          1.70          0.002
  O00757                                                     F16P2       Fructose-1,6-bisphosphatase isozyme 2                           1.51          0.020
  Q96A32                                                     MLRS        Myosin regulatory light chain 2, skeletal muscle isoform        1.70          0.007
  P13535                                                     MYH8        Myosin-8                                                        2.55          0.047
  P05976; Q15111                                             MYL1        Myosin light chain 1/3, skeletal muscle isoform                 1.61          0.009
  Q9UBF9                                                     MYOTI       Myotilin                                                        1.51          0.008
  O14974                                                     MYPT1       Protein phosphatase 1 regulatory subunit 12A                    1.54          0.021
  Q53GG5                                                     PDLI3       PDZ and LIM domain protein 3                                    1.93          0.000
  P60900                                                     PSA6        Proteasome subunit alpha type-6                                 1.56          0.017
  Q9UHP9                                                     SMPX        Small muscular protein                                          2.03          0.000
  A8MU46                                                     SMTL1       Smoothelin-like protein 1                                       2.05          0.003
  P23327                                                     SRCH        Sarcoplasmic reticulum histidine-rich calcium-binding protein   1.96          0.003
  Q9H7C4                                                     SYNCI       Syncoilin                                                       1.51          0.026
  O15061                                                     SYNEM       Synemin                                                         1.57          0.003
  Q8N3V7                                                     SYNPO       Synaptopodin                                                    1.82          0.016
  Q9NZQ9                                                     TMOD4       Tropomodulin-4                                                  1.92          0.002
  P02585; P27482                                             TNNC2       Troponin C, skeletal muscle                                     1.98          0.002
  P48788                                                     TNNI2       Troponin I, fast skeletal muscle                                1.98          0.006
  P07951; O75330                                             TPM2        Tropomyosin beta chain                                          1.88          0.000
  P06753                                                     TPM3        Tropomyosin alpha-3 chain                                       2.07          0.004
  Q9BYV2                                                     TRI54       Tripartite motif-containing protein 54                          2.15          0.033
  Only upregulated in PLA group after 12 weeks of training                                                                                             
  P02511                                                     CRYAB       Alpha-crystallin B chain                                        2.01          0.037
  Q6P5Q4                                                     LMOD2       Leiomodin-2                                                     2.80          0.014
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###### 

Upregulated proteins from the intersection, collagen (COL), and placebo (PLA) groups belonging to collagen proteins or collagen-associated proteins.

  UniProt                                     Gene Name   Protein Description             Fold Change (FC)          FDR           
  ------------------------------------------- ----------- ------------------------------- ------------------ ------ ----- ------- -------
  Upregulated in both groups after 12 weeks                                                                                       
  P12110                                      CO6A2       Collagen alpha-2(VI) chain      2.86               3.17         0.001   0.000
  P02751                                      FINC        Fibronectin                     4.46               2.24         0.007   0.021
  P11047                                      LAMC1       Laminin subunit gamma 1         1.90               1.71         0.023   0.022
  Only upregulated in COL after 12 weeks                                                                                          
  P20908                                      CO5A1       Collagen alpha-1(V) chain       108.74             \-           0.018   \-
  P39059                                      COFA1       Collagen alpha-1(XV) chain      1.69               \-           0.028   \-
  P39060                                      COIA1       Collagen alpha-1(XVIII) chain   2.85               \-           0.001   \-
  Only upregulated in PLA after 12 weeks                                                                                          
  P51884                                      LUM         Lumican                         \-                 1.59         \-      0.001
